Ferring and BioInnovation Institute enter new strategic collaboration to accelerate innovation in women’s health
18.4.2023 11:00:00 EEST | Business Wire | Press release
Ferring Pharmaceuticals and BioInnovation announce a new strategic collaboration to accelerate innovation in women’s health.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230418005217/en/
Ferring and BioInnovation Institute enter new strategic collaboration to accelerate innovation in women’s health (Photo: Business Wire)
BioInnovation Institute Foundation (BII) and Ferring Pharmaceuticals A/S (Ferring) have expanded their collaboration with the objective to accelerate world-class life science innovation within women’s health. New activities will include supporting BII to source, and potentially fund and incubate early-stage start-ups and projects within the field of reproductive medicine.
“The new strategic collaboration, highlights Ferring’s continued commitment to invest in early-stage innovation in this area, and we look forward to strengthening our collaboration with BII to accelerate new solutions for patients,” says Armin Metzger, Executive Vice President and Chief Science Officer at Ferring.
The strategic collaboration builds on Ferring’s engagement with BII’s Women’s Health Initiative through Ferring’s membership on the BII Women’s Health Innovation Panel. Women’s health is underserved as only 1% of global healthcare research funding is invested in female-specific conditions beyond oncology.1 The collaboration aims to bridge the gap by supporting early-stage innovation and will leverage BII’s proven expertise in translational science incubation, together with Ferring’s expertise in early-stage development and reproductive medicine.
“Combining BII’s already proven incubation expertise with the industrial expertise and deep insights that Ferring has within women’s health forms a very strong basis for supporting and accelerating our mission of getting more solutions on the market that address the high unmet needs of 50% of the world’s population. We are pleased to collaborate even closer with Ferring to make it happen,” says Trine Bartholdy, Chief Innovation Officer at the BioInnovation Institute.
About Ferring Pharmaceuticals:
Ferring Pharmaceuticals is a research-driven, specialty biopharmaceutical group committed to helping people around the world build families and live better lives. Headquartered in Saint-Prex, Switzerland, Ferring is a leader in reproductive medicine and maternal health, and in specialty areas within gastroenterology and urology. Ferring has been developing treatments for mothers and babies for over 50 years and has a portfolio covering treatments from conception to birth. Founded in 1950, privately-owned Ferring employs over 7,000 people worldwide. The company has operating subsidiaries in more than 50 countries and markets its products in over 100 countries.
Learn more at www.ferring.com, or connect with us on LinkedIn, Instagram, Facebook, Twitter and YouTube.
The BioInnovation Institute Foundation:
At BioInnovation Institute (BII), we accelerate world-class life science start-up innovation for the benefit of people and society. As a non-profit institute, BII operates the company creation programs, Bio Studio, Venture Lab and Venture House, to support life science start-ups with knowledge, network, infrastructure and funding of up to EUR 3 million per project and EUR 1,8 million per start-up. With our expertise, network, funding, and infrastructure, we empower start-ups to succeed and believe in the transformative power of life science innovation. Read more on www.bioinnovationinstitute.com.
1 McKinsey & Company. Unlocking opportunities in women’s healthcare. 2022. Available at: https://www.mckinsey.com/industries/healthcare/our-insights/unlocking-opportunities-in-womens-healthcare [Last accessed April 2023]
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230418005217/en/
Contact information
For more information, please contact:
Ferring Pharmaceuticals
Björn Lindström
Director, Corporate Communications & Public Affairs
+45 28 78 78 62
Bjoern.lindstroem@ferring.com
BioInnovation Institute
Casper Linnemann
Head of Communication
+45 4172 7994
cli@bii.dk
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
The smarter E Europe: The Special Exhibit Renewables 24/7 Shows How a Renewable Energy Supply Is Possible21.4.2026 14:00:00 EEST | Press release
The current geopolitical situation once again highlights the risks of depending on fossil fuels and the increasing need to transform our energy supply. Solar and wind power have long been established as cost-efficient energy sources, and the International Energy Agency (IEA) has predicted a global 2.6-fold capacity growth between 2022 and 2030. Against this backdrop, The smarter E Europe alliance of exhibitions will spotlight the feasibility of a renewable energy system from June 23–25 in Munich. The Special Exhibit Renewables 24/7 uses best practices, presentations and live demos to show how a round-the-clock renewable energy supply can be achieved. To kick off the exhibition on June 23, The smarter E Europe will present an exclusive accompanying study, conducted in collaboration with the Fraunhofer Institute for Solar Energy Systems, that dispels common myths about system stability and provides scientific proof that such an energy system is viable. The study, Pathways to a Renewable
The smarter E Europe: The Special Exhibit Renewables 24/7 Shows How a Renewable Energy Supply Is Possible21.4.2026 14:00:00 EEST | Press release
The current geopolitical situation once again highlights the risks of depending on fossil fuels and the increasing need to transform our energy supply. Solar and wind power have long been established as cost-efficient energy sources, and the International Energy Agency (IEA) has predicted a global 2.6-fold capacity growth between 2022 and 2030. Against this backdrop, The smarter E Europe alliance of exhibitions will spotlight the feasibility of a renewable energy system from June 23–25 in Munich. The Special Exhibit Renewables 24/7 uses best practices, presentations and live demos to show how a round-the-clock renewable energy supply can be achieved. To kick off the exhibition on June 23, The smarter E Europe will present an exclusive accompanying study, conducted in collaboration with the Fraunhofer Institute for Solar Energy Systems, that dispels common myths about system stability and provides scientific proof that such an energy system is viable. The study, Pathways to a Renewable
Compass Pathways Collaborates with Osmind to Advance Independent Clinic Readiness for Psychedelic Treatments21.4.2026 13:30:00 EEST | Press release
Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation announced today it has entered into a collaboration with Osmind, the platform powering a nationwide network of interventional psychiatry practices. This collaboration will inform how small-to-medium sized clinics nationwide can effectively deliver novel psychedelic treatments, if FDA approved. The agreement with Osmind further expands the set of collaborations that Compass has established to inform the potential delivery of COMP360 in a broad spectrum of settings where people living with mental health conditions receive their care in the United States. Osmind is a public benefit corporation advancing psychiatry through technology, services, and real-world evidence to bring innovative mental health treatments to patients in need. Osmind’s network of over 1,000 clinics comprises one of the country’s largest network of interventional psychiatry practices. Its
Compass Pathways Collaborates with Osmind to Advance Independent Clinic Readiness for Psychedelic Treatments21.4.2026 13:30:00 EEST | Press release
Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation announced today it has entered into a collaboration with Osmind, the platform powering a nationwide network of interventional psychiatry practices. This collaboration will inform how small-to-medium sized clinics nationwide can effectively deliver novel psychedelic treatments, if FDA approved. The agreement with Osmind further expands the set of collaborations that Compass has established to inform the potential delivery of COMP360 in a broad spectrum of settings where people living with mental health conditions receive their care in the United States. Osmind is a public benefit corporation advancing psychiatry through technology, services, and real-world evidence to bring innovative mental health treatments to patients in need. Osmind’s network of over 1,000 clinics comprises one of the country’s largest network of interventional psychiatry practices. Its
Aventon Expands B2B Payment Terms Program to Germany with TreviPay21.4.2026 12:00:00 EEST | Press release
TreviPay, a global B2B payments infrastructure partner, today announced the expansion of its partnership with Aventon to support the launch of the Aventon Payment Terms program in Germany. Building on the success of Aventon’s existing program in the US and Canada, the new offering will give qualified B2B buyers in Germany access to invoicing and flexible payment terms designed to make purchasing easier and more predictable. As Aventon enters the German market and expands its presence in Europe, TreviPay will serve as the exclusive provider of payment terms for Aventon’s B2B buyers. The program is designed to help Aventon’s retail partners buy more confidently and manage working capital more effectively, while supporting the brand’s long-term growth in a new geography. By offering trade credit through TreviPay, Aventon can give retailers greater purchasing flexibility and strengthen its ability to compete in a dynamic market. TreviPay research shows 78% of B2B buyers say offering invoic
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom